Drug intelligence / Profile preview

OriC-901

Development stage: Preclinical
Lead developer: OriCell Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

OriC-901 is a chimeric antigen receptor T cell (CAR-T) therapy targeting cadherin-17 (CDH17), under development by OriCell Therapeutics for the treatment of colorectal cancer. The drug is designed to recognize and bind to CDH17, a protein overexpressed in certain tumor cells, enabling targeted immune-mediated destruction of these cancer cells. As of the latest available information, OriC-901 is in preclinical development.

Targets

CDH17 (Cadherin-17)

Beyond the preview

Go deeper on OriC-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OriC-901.

Explore the full profile